Biotie Therapies - Prospectus/Announcement of Prospectus

A listing prospectus concerning listing of new shares in Biotie has been published

BIOTIE THERAPIES CORP.           STOCK EXCHANGE RELEASE    7 September 2012 at
4.45 p.m.

Not for release, publication or distribution, directly or indirectly, in whole
or in part, in or into the United States, Australia, Canada, Japan or South
Africa.

A listing prospectus concerning listing of new shares in Biotie has been
published

Regarding the directed issues ("Share Issues") of shares to H. Lundbeck A/S and
institutional and strategic investors announced by Biotie Therapies Corp.
("Biotie" or "Company") earlier today, Biotie has published a listing prospectus
approved by the Finnish Financial Supervisory Authority today ("Listing
Prospectus"). Biotie has published the Listing Prospectus solely for the
purposes of admission of the new shares to be issued pursuant to the resolutions
passed by the Board of Directors of Biotie to public trading on NASDAQ OMX
Helsinki Ltd. Biotie does not offer any securities on the basis of the Listing
Prospectus.

The Company will use the proceeds of the Share Issues to bridge the gap in
reaching a potential revenue stream of Selincro and potential milestone payments
of other portfolio compounds, to strengthen its working capital and balance
sheet ahead of partnering (in/out licensing) discussions, and to finance
development of potential new R&D programs to next significant value inflection
points.

The marketing authorisation application for Selincro was accepted for review by
the European Medicine Agency in December 2011. Feedback from the Agency is
expected H2 2012. As the exclusivity period starts from the approval, management
of the Company expects European launch of Selincro to follow thereafter during
2013.

The Listing Prospectus and a Finnish language translation of the summary will be
available at the headquarters of Biotie at Tykistökatu 6, FI-20520 Turku,
Finland as of 10 September 2012. The Listing Prospectus and a Finnish language
translation of the summary will also be available on the Company's homepage at
www.biotie.com as of 7 September 2012. The Listing Prospectus is available only
in English.

In Turku, 7 September 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
www.biotie.com

DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease.The company has a strong and balanced development portfolio with
several innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases with high
unmet medical need and significant market potential.

Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant
for Parkinson's disease. The Marketing Authorization Application for Biotie's
most advanced product, SelincroTM (nalmefene) for alcohol dependence was filed
in the EU by our partner H. Lundbeck A/S and was accepted for review by the
European Medicines Agency in December 2011. Biotie shares are listed on NASDAQ
OMX Helsinki Ltd.


[HUG#1639616]